chiglitazar

Chiglitazar is a novel small molecule drug developed as a peroxisome proliferator-activated receptor (PPAR) pan-agonist. It simultaneously activates all three PPAR subtypes (α, γ, and δ), leading to improved insulin sensitivity and regulation of glucose and lipid metabolism. By targeting the core pathophysiology of type 2 diabetes—insulin resistance—chiglitazar modulates gene expression related to fatty acid oxidation, energy conversion, and lipid transport. It is the world’s first approved PPAR pan-agonist for type 2 diabetes mellitus (T2DM), offering a new mechanism distinct from existing antidiabetic agents. The drug was independently developed in China by Chipscreen Biosciences and is indicated for improving glycemic control in adults with T2DM as monotherapy or in combination with other agents such as metformin. Clinical studies have also explored its use in nonalcoholic steatohepatitis (NASH). Metabolism occurs primarily via hepatic CYP3A enzymes[1][2][4][6].

Brand names

双洛平Bilessglu

Other names

西格列他钠Chiglitazar Sodium Tablets